Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge is advising Immunovia in connection with its rights issue of up to SEK 202 million
Mandate

Vinge is advising Immunovia in connection with its rights issue of up to SEK 202 million

February 20, 2023 Capital Markets and Public M&A

Immunovia AB (publ) is a diagnostic company with the vision to revolutionize blood-based diagnostics and increase survival rates for patients with cancer. Immunovia’s shares are listed on Nasdaq Stockholm.

Vinge’s team primarily consisted of Dain Hård Nevonen, Amanda Knutsson, Anders Sundin Lundberg and Adrian Filipovic.

Related news

Vinge advises Ramirent in connection with its acquisition of JIAB

 Vinge advises Ramirent AB in connection with its acquisition of JIAB Hyrcenter (consisting of the companies JIAB Hyrcenter AB and JIAB Boden AB). Ramirent thereby further strengthens its position in Norrbotten and as the largest machine rental company in Sweden.
March 21, 2023

Vinge has advised Svea Bank AB in connection with the issuance of Additional Tier 1 Capital of SEK 300 million

 Vinge has advised Svea Bank AB (the “Company”) in connection with its issuance of additional tier 1 capital (AT1) of SEK 300 million to optimise its capital structure.
March 14, 2023

Vinge advises Anglo American in connection with investment in the Dannemora mine

 Vinge has, together with Norton Rose Fulbright, advised Anglo American Limited in connection with entering into a royalty agreement of USD 10 million and a binding term sheet for an offtake agreement with Dannemora Iron AB. Moreover, Vinge has assisted with thereto related due diligence. Dannemora Iron AB is a wholly owned subsidiary of Grängesberg Exploration Holding AB (publ).
March 14, 2023